Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 2Phase EARLY_PHASE1 1Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 6Melanoma 4Skin Neoplasms 2Neoplasm Metastasis 2Carcinoma, Squamous Cell 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Recurrence 1Kidney Neoplasms 1Eyelid Squamous Cell Carcinoma 1Cutaneous Squamous Cell Carcinoma 1Colorectal Neoplasms 1Cholangiocarcinoma 1Carcinoma, Merkel Cell 1Carcinoma, Large Cell 1Carcinoma, Hepatocellular 1Brain Neoplasms 1Anus Neoplasms 1Adenocarcinoma 1

Interventions

pembrolizumab 2cemiplimab 1avelumab 1atezolizumab 1Saline Solution 1Nivolumab 1Ipilimumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Carcinoma, Merkel Cell × cemiplimab × Clear all
NCT04157985 2025-12-11

Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors

University of Pittsburgh

Phase 3 Completed
161 enrolled
DermatologicGastrointestinalGenitourinaryGynecologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Anus Neoplasms, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Kidney Neoplasms, Melanoma, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡